Form 4: Travere Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Sandra Calvin, SVP, CHIEF ACCOUNTING OFFICER of Travere Therapeutics, Inc., sold 5,375 shares of common stock on September 15, 2026.
Summary
- Option exercise/conversion: acquired 2,500 Common Stock at $27.50 ($68,750) on September 15, 2026; holds 44,853 after (Direct).
- Option exercise/conversion: acquired 1,250 Common Stock at $22.40 ($28,000) on September 15, 2026; holds 46,103 after (Direct).
- Option exercise/conversion: acquired 1,625 Common Stock at $20.46 ($33,248) on September 15, 2026; holds 47,728 after (Direct).
- Open-market sale: disposed of 4,275 Common Stock at $62.13 ($265,627) on September 15, 2026; holds 43,453 after (Direct).
- Open-market sale: disposed of 800 Common Stock at $62.85 ($50,278) on September 15, 2026; holds 42,653 after (Direct).
- Open-market sale: disposed of 300 Common Stock at $63.66 ($19,099) on September 15, 2026; holds 42,353 after (Direct).
- Option exercise/conversion: disposed of 2,500 Employee stock option (right to buy) on September 15, 2026 (Direct).
- Option exercise/conversion: disposed of 1,250 Employee stock option (right to buy) on September 15, 2026; holds 3,750 after (Direct).
- Option exercise/conversion: disposed of 1,625 Employee stock option (right to buy) on September 15, 2026; holds 17,875 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $335,005 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Sandra Calvin — Officer (SVP, CHIEF ACCOUNTING OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Option exercise/conversion | Common Stock | 2,500 | $28 | $68.8K | 44,853 |
| 2026-09-15 | Option exercise/conversion | Common Stock | 1,250 | $22 | $28.0K | 46,103 |
| 2026-09-15 | Option exercise/conversion | Common Stock | 1,625 | $20 | $33.2K | 47,728 |
| 2026-09-15 | Open-market sale | Common Stock | 4,275 | $62 | $265.6K | 43,453 |
| 2026-09-15 | Open-market sale | Common Stock | 800 | $63 | $50.3K | 42,653 |
| 2026-09-15 | Open-market sale | Common Stock | 300 | $64 | $19.1K | 42,353 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 2,500 | — | — | 0 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 1,250 | — | — | 3,750 |
| 2026-09-15 | Option exercise/conversion | Employee stock option (right to buy) | 1,625 | — | — | 17,875 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Option exercise/conversion (2,500 shares) |
| 2026-09-15 | Option exercise/conversion (1,250 shares) |
| 2026-09-15 | Option exercise/conversion (1,625 shares) |
| 2026-09-15 | Open-market sale (4,275 shares) |
| 2026-09-15 | Open-market sale (800 shares) |
| 2026-09-15 | Open-market sale (300 shares) |
| 2026-09-15 | Option exercise/conversion (2,500 shares) |
| 2026-09-15 | Option exercise/conversion (1,250 shares) |
| 2026-09-15 | Option exercise/conversion (1,625 shares) |
Keywords
insider transaction, Form 4, TVTX, Travere Therapeutics, Inc., bearish, Sandra Calvin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.